BioCentury
ARTICLE | Clinical News

Protovir human antibody targeted to cytomegalovirus data

April 15, 2013 7:00 AM UTC

PDLI announced results of Phase II testing in 179 people, with a preliminary analysis showing lower incidence of infection, death, or relapse of disease (the primary end points of the trial). The difference was statistically significant versus control patients at 98 days after allogeneic bone marrow transplant (p=0.003).

Fewer patients treated with the higher dose of the antibody reached the primary end points, compared to patients on the lower doses or placebo (61 percent, compared to 72 percent with either low dose or placebo; p=0.16, not statistically significant), regardless of prior CMV status. In CMV naive patients, the percent reaching the primary end points was statistically significantly lower in the treatment groups compared to placebo (24 versus 70 percent respectively). The stratification according to CMV serotype was prospective. ...